Dept of Biopathology, Tor Vergata University of Rome, via Montpellier 131, 00133 Rome, Italy.
Eur Respir J. 2012 Feb;39(2):446-57. doi: 10.1183/09031936.00005511. Epub 2011 Jun 30.
Alveolar type II pneumocytes (ATII cells) are considered putative alveolar stem cells. Since no treatment is available to repair damaged epithelium and prevent lung fibrosis, novel approaches to induce regeneration of injured alveolar epithelium are desired. The objective of this study was to assess both the capacity of human embryonic stem cells (HUES-3) to differentiate in vitro into ATII cells and the ability of committed HUES-3 cells (HUES-3-ATII cells) to recover in vivo a pulmonary fibrosis model obtained by silica-induced damage. In vitro differentiated HUES-3-ATII cells displayed an alveolar phenotype characterised by multi-lamellar body and tight junction formation, by the expression of specific markers such as surfactant protein (SP)-B, SP-C and zonula occludens (ZO)-1 and the activity of cystic fibrosis transmembrane conductance regulator-mediated chloride ion transport. After transplantation of HUES-3-ATII cells into silica-damaged mice, histological and biomolecular analyses revealed a significant reduction of inflammation and fibrosis markers along with lung function improvement, weight recovery and increased survival. The persistence of human SP-C, human nuclear antigen and human DNA in the engrafted lungs indicates that differentiated cells remained engrafted up to 10 weeks. In conclusion, cell therapy using HUES-3 cells may be considered a promising approach to lung injury repair.
肺泡 II 型上皮细胞(ATII 细胞)被认为是潜在的肺泡干细胞。由于目前尚无治疗方法可修复受损的上皮细胞并预防肺纤维化,因此需要寻求新的方法来诱导受损的肺泡上皮细胞再生。本研究的目的是评估人胚胎干细胞(HUES-3)在体外分化为 ATII 细胞的能力,以及定向分化的 HUES-3 细胞(HUES-3-ATII 细胞)在体内恢复由二氧化硅诱导损伤引起的肺纤维化模型的能力。体外分化的 HUES-3-ATII 细胞表现出肺泡表型,其特征在于多板层小体和紧密连接的形成,表达特定标志物,如表面活性剂蛋白(SP)-B、SP-C 和闭合蛋白(ZO)-1,以及囊性纤维化跨膜电导调节蛋白介导的氯离子转运的活性。将 HUES-3-ATII 细胞移植到二氧化硅损伤的小鼠体内后,组织学和生物分子分析显示炎症和纤维化标志物显著减少,同时肺功能得到改善,体重恢复,存活率提高。植入肺部的人类 SP-C、人类核抗原和人类 DNA 的持续存在表明分化细胞在 10 周内仍保持植入。总之,使用 HUES-3 细胞的细胞治疗可能被认为是修复肺损伤的一种有前途的方法。